- Home
- OXM vs ABUS Comparison
OXM vs ABUS Comparison
Compare OXM & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXM
- ABUS
- Stock Information
- Founded
- OXM 1942
- ABUS 2005
- Country
- OXM United States
- ABUS United States
- Employees
- OXM N/A
- ABUS N/A
- Industry
- OXM Apparel
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- OXM Consumer Discretionary
- ABUS Health Care
- Exchange
- OXM Nasdaq
- ABUS Nasdaq
- Market Cap
- OXM 687.3M
- ABUS 711.2M
- IPO Year
- OXM N/A
- ABUS N/A
- Fundamental
- Price
- OXM $40.63
- ABUS $4.38
- Analyst Decision
- OXM Hold
- ABUS Strong Buy
- Analyst Count
- OXM 6
- ABUS 2
- Target Price
- OXM $54.40
- ABUS $5.00
- AVG Volume (30 Days)
- OXM 592.1K
- ABUS 1.4M
- Earning Date
- OXM 09-10-2025
- ABUS 11-05-2025
- Dividend Yield
- OXM 6.79%
- ABUS N/A
- EPS Growth
- OXM 94.17
- ABUS N/A
- EPS
- OXM 3.67
- ABUS N/A
- Revenue
- OXM $1,494,535,000.00
- ABUS $15,416,000.00
- Revenue This Year
- OXM $0.29
- ABUS $138.02
- Revenue Next Year
- OXM $1.91
- ABUS N/A
- P/E Ratio
- OXM $11.08
- ABUS N/A
- Revenue Growth
- OXM N/A
- ABUS 53.23
- 52 Week Low
- OXM $36.25
- ABUS $2.71
- 52 Week High
- OXM $89.86
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- OXM 41.87
- ABUS 54.52
- Support Level
- OXM $39.48
- ABUS $4.25
- Resistance Level
- OXM $41.72
- ABUS $4.66
- Average True Range (ATR)
- OXM 1.66
- ABUS 0.17
- MACD
- OXM -0.43
- ABUS -0.03
- Stochastic Oscillator
- OXM 12.97
- ABUS 41.67
About OXM Oxford Industries Inc.
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates majority of its revenue from the Tommy Bahama division.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.